Eli Lilly and Co.; Announcement of the Revocation of the Biologics License for LARTRUVO

الملخص

The Food and Drug Administration (FDA or Agency) is announcing the revocation of the biologics license application (BLA) for LARTRUVO (olaratumab) injection. Eli Lilly and Co. requested withdrawal (revocation) of the biologics license application and has waived its opportunity for a hearing.